Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company, announced it will host a virtual key opinion leader $(KOL)$ event on June 16, 2025, to discuss the positive results from a Phase 3 clinical trial of denifanstat, a novel treatment for moderate to severe acne vulgaris. The trial, conducted in China by Ascletis, Sagimet's license partner, demonstrated that denifanstat, a once-daily oral fatty acid synthase (FASN) inhibitor, met all primary and secondary endpoints versus placebo and was generally well tolerated. The event will feature insights from Neal Bhatia, MD, and include a live Q&A session. Additionally, Sagimet will discuss its newly initiated Phase 1 study for its second FASN inhibitor drug candidate, TVB-3567, intended for acne treatment in the U.S. A replay of the event will be available on Sagimet's website for 90 days post-event.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。